ANI Pharmaceuticals Inc (NAS:ANIP)
$ 54.41 -1.09 (-1.96%) Market Cap: 1.14 Bil Enterprise Value: 1.64 Bil PE Ratio: 0 PB Ratio: 2.82 GF Score: 85/100

ANI Pharmaceuticals Inc at Raymond James Human Health Innovation Conference (Virtual) Transcript

Jun 22, 2021 / 04:00PM GMT
Release Date Price: $33.16 (-1.37%)
Elliot Wilbur
Raymond James - Analyst

Good afternoon. Welcome to the ANI Pharmaceuticals presentation and update at Raymond James Annual Health and Human Innovation Conference. My name is Elliot Wilbur. I'm the coverage analyst on ANI and covering the specialty pharmaceutical space for Raymond James. For those of you not familiar with ANI Pharma, it's a Company with its foundation built in the generics industry but has rapidly pivoted towards repositioning itself as a US-focused biopharma story with multiple growth platforms, spanning both the brand and generic drug sectors.

Providing us with an update on recent developments is the Company's Chief Executive Officer, Nikhil Lalwani; and we also are joined by the Company's Chief Financial Officer, Steve Carey. So with that, the floor is yours, Nikhil.

Nikhil Lalwani
ANI Pharmaceuticals, Inc. - President and CEO

Thank you, Elliot. I'll go ahead and share my screen. Can you see it?

Elliot Wilbur
Raymond James - Analyst

Yes, we can see it. You're good to go,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot